Lynn is a biotech entrepreneur and the founder of STALICLA SA. Her lifelong involvement with the Autism community has brought her to develop a unique patient centric vision of Drug Development to address the unmet medical needs of patients with Autism Spectrum Disorder. Fostering on a strong network within the neuroscience, clinical research and data science communities, she launched STALICLA in May 2017 and is leading its early fast-paced growth. Lynn has extensive experience in Business development and has worked in the past for the World Economic forum, venture capital and start-up promoting initiatives. Lynn holds a double degree in economic history and political sciences and a Master’s degree from Rouen Business School. She is also currently finalizing a post graduate degree in clinical trials and drug development at the Faculty of medicine of the University of Geneva.
Luigi is a research scientist and clinical geneticist at the Greenwood Genetic Center (GGC). His research focuses on autism spectrum disorder, intellectual disability and overgrowth conditions. He holds a position as Assistant Professor at the Clemson University School of Health Research. He works around the definition of metabolomics profiles applied to several genetic conditions with a special focus on pathogenic mechanisms and molecular biomarkers identification, as well as novel treatment strategies development.
Jean-Marc is a scientist in cellular and molecular biology, and project manager with ten years of experience in academic research laboratories and eight years in pharmaceutical companies. He has been instrumental in directing and improving processes, enhancing productivity, and implementing technology solutions in various drug/medtech development projects. He is skilled in spearheading research and innovation activity in corporate settings and has a strong ability to develop and maintain partnerships.
Joseph has 20 years' experience in drug discovery on the R&D interface. He has held various leading positions in the industry as former Head of Psychiatry Disease area and Vice President, Neurosciences, at Roche. Prior to that, he held the positions of Director, Systems Pharmacology CNS Research at SANOFI and ITEM Scientific Director.
Kevin has 25+ year’ experience in biomedical research and translational drug development applied to Neurosciences. Kevin is an Advisor for the BaseLaunch accelerator initiative for healthcare ventures. Prior to this he was Executive Director in the Neuroscience Disease Area, Novartis Institutes for Biomedical Research, and Principal Medical Scientific Expert in the Novartis Neuroscience Development Franchise. Kevin holds a PhD in Behavioural Pharmacology from the University of Wales, UK, and an MBA from the International Institute for Management Development, Lausanne, Switzerland.
Kirstie has eight years’ experience working for leading entrepreneurs internationally in Melbourne, London and Geneva. She is responsible for administrative coordination, liaising with external accounting offices and statutory auditors.